Search results
Showing 61 to 75 of 114 results for chronic heart failure in adults: management
Evidence-based recommendations on short-term circulatory support with left ventricular assist devices (LVAD) as a bridge to heart transplantation or recovery. This involves inserting a mechanical device into the chest to help the heart pump blood around the body.
View recommendations for HTG115Show all sections
Sections for HTG115
Our guidance helps you hand over care and ensure people are safely transitioned out of the virtual ward environment.
EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)
NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration
The OPTIMIZER smart system for managing heart failure (MIB186)
NICE has developed a medtech innovation briefing (MIB) on the OPTIMIZER smart system for managing heart failure .
Read biographies for all members of NICE's indicator advisory committee.
ENDURALIFE powered CRT-D devices for treating heart failure (HTG433)
Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
Read biographies for all members of NICE's indicator advisory committee.
Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)
Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.
This guideline has been updated and replaced by NICE guideline NG106.
Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices.
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.